UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 91 - 105 of 671

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Basic Mechanisms of Urgency: Preclinical and Clinical Evidence - Abstract
Thursday, 09 July 2009
Department of Pharmacology and Pharmacotherapy, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
read more

The Safety and Efficacy of Tolterodine Extended Release in the Treatment of Overactive Bladder in the Elderly - Abstract
Wednesday, 08 July 2009
Department of Geriatric Medicine, University College Hospital, London, UK.
read more

Efficacy and Tolerability of Fesoterodine in Women With Overactive Bladder - Abstract
Tuesday, 07 July 2009
Evanston Continence Center, Department of Obstetrics and Gynecology, Northwestern University, Feinberg School of Medicine, 1000 Central Street, Suite 730, Evanston, IL 60201, USA.
read more

Urgency-Free Time Interval as Primary Endpoint for Evaluating the Outcome of a Randomized OAB Treatment - Abstract
Monday, 06 July 2009
Division of Female Pelvic Medicine and Reconstructive Surgery, Chang Gung Memorial Hospital, Linko, Taiwan.
read more

Drug Treatment of Urological Symptoms: Estimating the Magnitude of Unmet Need in a Community-Based Sample - Abstract
Monday, 06 July 2009
Division of Urologic Surgery, Brigham and Women's Hospital, Boston, MA.
read more

Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder: Results from the MATRIX Study - Abstract
Friday, 03 July 2009
Doris N. Grandon Center for Health Economics and Outcomes Research, Jefferson School of Population Health, Philadelphia, Pennsylvania, USA.
read more

Nonneurogenic Voiding Disorders: What's New? - Abstract
Thursday, 02 July 2009
Division of Pediatric Urology, Morgan Stanley Children's Hospital of New York-Presbyterian, New York NY 10032, USA.
read more

Neuromodulation 10 Years On: How Widely Should We Use This Technique in Bladder Dysfunction? - Abstract
Wednesday, 01 July 2009
Department of Urology, Pinderfields Hospital, Mid Yorkshire Hospitals, NHS Trust, Wakefield, West Yorkshire, UK.
read more

Neuromodulation and Female Sexual Function: Does Treatment for Refractory Voiding Symptoms Have An Added Benefit? - Abstract
Tuesday, 30 June 2009
Department of Urology, Ministrelli Program for Urology Research and Education (MPURE), William Beaumont Hospital, 3535 W. Thirteen Mile Rd Suite 438, Royal Oak, MI, 48073, USA.
read more

Baseline Incontinence Severity is Predictive of the Percentage of Patients Continent After Receiving Once-Daily Trospium Chloride Extended Release - Abstract
Tuesday, 30 June 2009
Division of Urology, Caritas-St. Elizabeth's Medical Center, Tufts University Medical School, Boston, MA 02135, USA.
read more

Pharmacological Treatment of Overactive Bladder: Report from the International Consultation on Incontinence - Abstract
Monday, 29 June 2009
Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, North Carolina 27157, USA.
read more

The International Continence Society Announces the First World Continence Week to be Held From Monday June 22nd to Sunday June 28th 2009 (with Subsequent World Continence Weeks Held Yearly in the Last Week of June)
Wednesday, 24 June 2009
BERKELEY, CA, USA (Press Release) - June 24, 2009
read more

Dr. Terry Mason of WVON Radio Reports on World Continence Week Activities
Monday, 22 June 2009
CHICAGO, IL, USA (News Release) - June 22, 2009
read more

Patient-Reported Most Bothersome Symptoms in OAB: Post Hoc Analysis of Data From a Large, Open-Label Trial of Solifenacin - Abstract
Thursday, 18 June 2009
Division of Urogynecology, Department of Obstetrics & Gynecology, Evanston Continence Center, NorthShore University HealthSystem, Northwestern University, Feinberg School of Medicine, Evanston, IL 60201, USA.
read more

Urinary Incontinence and Overactive Bladder in Patients With Heart Failure - Abstract
Thursday, 18 June 2009
School of Nursing, University of North Carolina, Chapel Hill, North Carolina 27704, USA.
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder